Introduction {#Sec1}
============

5-Fluorouracil (5-FU) has been the backbone of treatment for gastrointestinal cancer (GI-cancer) since the discovery of its efficacy in the fifties. In spite of the wide experience in clinical oncology, there are still controversies regarding the optimal administration of the drug. The latest development with an oral administration of the prodrug capecitabine opened new possibilities in this matter \[[@CR1]\]. In this pilot study of patients with tumors in the GI tract, the efficacy of continuous metronomic capecitabine was explored. We investigated both the tolerability and the best response to treatment.

Another goal with the study was to investigate whether the drug was efficient in an elderly patient population given in a continuously low-dose setting.

This was the only alternative to treat the patients since the normal standard chemotherapy regimen was considered too toxic. Here, patients with severe side effects from conventional treatment were included.

Materials and methods {#Sec2}
=====================

Study design and patients {#Sec3}
-------------------------

This pilot study included 35 patients in stage IV (GI-cancer) with primary metastatic or recurrent disease planned for treatment during 2010--2012. Patients were recruited from one county in Sweden. Seventeen of the 35 patients were more than 70 years of age, ranging from 29 to 86 years.

Many of the patients were pretreated with conventional chemotherapy before treatment with low-dose capecitabine.

The group treated with metronomic capecitabine in the first line was patients who were not considered suitable for conventional treatment mostly because of high age or medical contraindications. The group with this treatment in second line was generally patients with severe side effects after conventional chemotherapy.

We divided the patients into two groups as shown in Fig. [1](#Fig1){ref-type="fig"}; one group with upper GI-cancer and one with lower GI-cancer.Fig. 1The number of patients in the two groups with upper and lower GI-cancer

The malignancies representing the upper GI-cancer were carcinoma of the esophagus, the hepatobiliary system and the pancreas. Malignancies representing the lower GI-cancer were carcinoma of the colon and rectum.

The treatment with low-dose capecitabine (500 mg × 2) was considered for patient with a high age who received toxicity grade III--IV to prior chemotherapy or because evidence-based alternatives had already been tested.

The patients were followed every 4th week with clinical examination and laboratory measurements in an outpatient basis. Radiological examination with response evaluation was done approximately after 2 months of treatment, and RECIST criteria were used.

The patient data included the information of recurrent disease, start of treatment with low-dose capecitabine, the reason for treatment as well as duration of treatment. Other anticancer drugs during study were noted and also other malignancies present.

Since the follow-up was quite frequent, the best response during the treatment for most patients could be easily determined. End points used in this study were progress, regress or stable disease as well as the cases where no assessment of response was possible.

Results {#Sec4}
=======

Since the material is heterogeneous, we wish to illustrate them by describing three individual cases as following.

The first patient received treatment with capecitabine and bevacizumab as the fifth line of treatment (Nr 28) (see Table [1](#Tab1){ref-type="table"}) was a women born in 1973. She was diagnosed with cecal cancer in 2003. There was a doctor delay of more than a year, and when she finally was diagnosed, she had metastatic disease. She lived with metastatic disease for 9.5 years with intermittent chemotherapy and most of the time with good quality of life (QoL). Shortly, before her death, she participated in a horse show competition. She received metronomic capecitabine and bevacizumab for 2 years.Table 1Patient dataCaseDate of diagnosisMonths until recurrence from date of operationYear of recurrenceStart of treatmentDays of survival from date of diagnosisDate of death1April 20092010January 20121,138May 20122October 2007292010December 20111,635April 20123August 201042011December 20114August 2009242011January 20125November 2008162010January 20116November 2010102011March 20127November 2011March 20128March 2009August 2009447May 20109October 2009December 2011912April 201210May 2010September 2011400June 201111August 201052011December 201112August 2009?2011812November 201113December 2006492011May 20111,736September 201114April 2006242008April 20112,223May 201215October 201016September 2010January 201117December 2007482012August 201118July 200742008July 20111,552October 201119August 2004762011September 201120September 2010January 201121June 2011September 201122October 2010August 2011379November 201123December 2005562010January 20112,181November 201124October 2008142010April 201125October 2011October 201168December 201126March 2007102008August 20101,757January 201227March 2007342010September 20101,512April 201128July 2003August 20093,109January 201229October 2004362007November 20112,740April 201230April 2012May 201231June 2010April 201232September 2011March 201233August 201032011May 201234January 201152011June 201235March 2011November 2011

The second patient (NR 20) (Table [1](#Tab1){ref-type="table"}) is a younger man born in 1977. He was diagnosed in 2010 with cancer of the hepatobiliary system and lung metastases. He started with conventional chemotherapy with severe side effects after two cycles. He was motivated for treatment but not physically fit which was the incitement to switch to metronomic capecitabine. A partial regression (PR) was observed. Radiofrequency (RF) treatment was given to a complete response in the liver in October 2012. He has shown stable disease by now for more than 2 years in the lungs being able to work full time and is alive and well.

The third patient receiving metronomic capecitabine (NR 21) (see Table [1](#Tab1){ref-type="table"}) is a man with adenocarcinoma diagnosed with a liver biopsy at the age of 86 years. When diagnosed, the multidisciplinary team conference hesitated to give him treatment. While still motivated for treatment, he made sure to be accepted for doctors' appointment at the oncology department. Treatment was started with metronomic capecitabine and was well tolerated without any side effects. Three months later, radiology confirmed regress of the disease, however, not a PR. He had stable disease for 1 year. Because of progress, he is now without tumor-specific treatment and has lived 2 years with good QoL and no side effects of treatment. Since his response to the treatment was good, he was reconsidered for local treatment. Because of the location of the tumor nearby big vessels, RF treatment was not an alternative. He was offered stereotactic treatment but declined when he was informed of possible side effects. He is alive and well.

Within the group selected for this treatment because of unacceptable toxicity grade III--IV (13 patients), only 3 of them were 75 years or older.

In the group with upper GI-cancer, about 30 % (*n* = 4) showed regress of disease (PR), 23 % (*n* = 3) progress and 46 % (*n* = 6) stable disease. In the group with lower GI-cancer, about 61 % (*n* = 11) showed progress and 39 % (*n* = 7) stable disease.

Figure [2](#Fig2){ref-type="fig"} shows best response divided between men and women, and Fig. [3](#Fig3){ref-type="fig"} shows the duration of treatment for both men and women in the two groups. Obviously, treatment duration was longer for upper GI-cancer. Still, the median duration of treatment was quite long for both groups. As shown in Fig. [3](#Fig3){ref-type="fig"}, one patient with the duration of treatment of 822 days was the young woman described above (NR 28). The other two dots present other two patients with an exceptional long duration of treatment.Fig. 2Best response in both groupsFig. 3Duration of treatment

Discussion {#Sec5}
==========

The number of people diagnosed with cancer is increasing in Sweden. One of the reasons is thought to be an increasing healthy elderly population.

A woman of 65 years old has a life expectancy of 20 years more and man about 18 years. About 60 % of the patients diagnosed with cancer are 65 year or older. Still, they are rarely included in research studies regarding new methods or treatments. Studies from USA as well as Sweden show that there are a great number of older patients not receiving any antitumor treatment at all \[[@CR2]\]. The reason is not yet established but might be the lack of information of proven therapies as well as resignation.

Colorectal cancer is the third most common diagnosis among both men and women in Sweden. There are approximately 5,000 new cases of colorectal cancer diagnosed every year. Almost half of those are over 75 years old.

The incidence increases with increasing age and doubles every seventh years for patients over 50 years of age. There is a lack of information about the optimal treatment regarding efficacy as well as QoL in patients suffering from CRC over 70 years of age, who often suffer from other diseases as well. Within the palliative setting, it is important to try to prevent disease progression without compromising patients QoL more than necessary. A continuous low-dose approach is not commonly used for patients with gastrointestinal cancer; however, earlier reports have been done both for esophageal cancer, breast cancer and prostatic cancer \[[@CR3]\]. The patients within this report were those with very severe side effects with conventional treatment and patients with an old age where the clinician hesitated to offer conventional toxic treatment. Moreover, a group of patients were palliated during a long period where the conventional treatment regimes all have been explored.

Of these 35 patients, six are still alive more than 24 months after initiation of treatment, all with active disease but stable disease and good QoL. Of these six, two had mucous adenocarcinoma, which we know is often therapy resistant, three patients had cholangiocarcinoma and one had adenocarcinoma in the liver.

Age is measured chronologically in many circumstances. From a medical perspective, the chronological age is more irrelevant as the patient becomes older. In a group of 80 years old, you can find healthy physically active people, and persons with many diseases who require a lot of care and help. Differences in treatment can be motivated but sometimes motivations for the differences are not fully explained other than the chronological age of the patient.

With the help of magnetic resonance imaging (MRI) and computed tomography (CT), we can study the affected organ/organs with accuracy. The disadvantage of this is also that we receive more information than we would like, as we can notice other pathologies not symptomatic for the patient. Since this is seen especially in older patients, examination with MRI or CT is excluded in many cases even though metastases will not be found. This is not acceptable, and neither is the fact that many older patients are excluded from multidisciplinary conferences.

The relative 5-year survival for all cancer diagnoses today is 67%, and 36 % in the beginning of the 70s indicating that the prognosis for cancer patients has improved tremendously \[[@CR4]\].

It is important to give optimal treatment to patients with colorectal cancer. However, there is a lack of information on treatment efficiency and safety for CRC in the oldest to old patients often suffering from underlying comorbidity. Lack of precise knowledge may also influence an option of providing a palliative care only \[[@CR5], [@CR6]\].

Our study shows that for the patient with toxicity to conventional chemotherapy or old age, metronomic capecitabine (Xeloda) can serve as an alternative treatment. Both tumor regression and SD were observed.

This study could be the incitement for a future randomized prospective study among the elderly patient group. A proper patient group would be patients with an age of 75 years or older with metastatic CRC disease, an ECOG performance status of 0--1 with acceptable hematological, liver and renal function tests. Results from such a study will fill a huge knowledge gap benefitting the emerging elderly population with CRC.
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